Meglumine antimoniate
| Meglumine Antimoniate |
|---|
| GLUCANTIM® WHO Prescribing Information |
| Description |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Dosage and Administration |
| How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Meglumine antimonate
Overview
Meglumine antimoniate is a medicine used for treating leishmaniasis. It is manufactured by Aventis and sold as Glucantime in France, and Glucantim in Italy.
It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.
Category
Antiparasitic
Brand Names
GLUCANTIM®, GLUCANTIME® (NOT AVAILABLE)
WHO Model Prescribing Information
Description | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Dosage and Administration | How Supplied
Mechanism of Action
The mechanism of action of meglumine antimoniate is unknown, but may involve inhibition of the parasite's glycolytic and fatty acid oxidative activity resulting in decreased reducing equivalents for antioxidant defense and decreased synthesis of adenosine triphosphate (ATP).